Automating correct inhaler technique in asthma & COPD with the aflo platform
Eradicating technique errors, improving symptom control and reducing the carbon footprint of Metered Dose Inhalers
Managing your airways condition
aflo™ automates inhaler technique to improve the management of respiratory conditions for patients and clinicians, saving lives, reducing costs and improving outcomes. Clinical trial data shows improved inhaler technique scores and better symptom control. Get in touch to learn about our clinical trials.
The scale of the problem
Estimates of those making inhaler errors range up to 90% of patients irrespective of the device type used*. This leads to poor symptom control, increased risk of hospitalisation and a higher risk of mortality. The aflo platform demonstrates a reduction in inhaler errors and better symptom control**.
*Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes Usmani et al. Respiratory Research (2018) 19:10 DOI 10.1186/s12931-017-0710-y.
** trial data in preparation
By 2025 asthma prevalence will rise to 400 million and by 2032 COPD will be the leading cause of death.
In the UK and Ireland alone there are over 5.9 million people diagnosed with asthma and over 1.4 million with COPD using inhaled medications.
- Inhaler technique error is associated with poorer outcomes in asthma and COPD
- Improving inhaler technique results in improved Quality of Life (QoL) scores
- Inhaler technique error increases healthcare costs
Where aflo makes the difference
.svg)
.svg)
.svg)
'When will it be available? I'm really going to miss having it to help me use my inhaler the right way.'
Clinical trial patient 2023
Reduce your symptoms with aflo
aflo™ will teach you how to inhale your medicines correctly and combine your daily inhalation scores with air quality and behaviour data to help you to manage the symptoms that reduce your quality of life.
